NEUP Financials Neuphoria Therapeutics Inc.
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $16M | -$400000 | 0.0% | -7.2% | — | — | $14M |
| 2024 | — | -$15M | — | — | — | — | $13M |
| 2023 | — | -$21M | — | — | — | — | $12M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$505063 | — | — | — | — | $19M |
| Dec '25 | — | $2M | — | — | — | — | $22M |
| Sep '25 | — | -$10M | — | — | — | — | $14M |
| Jun '25 | -$13267 | -$9M | 0.0% | 43981.7% | — | — | $14M |
| Mar '25 | $15M | $11M | 0.0% | 79.8% | — | — | $17M |
| Dec '24 | $662715 | -$2M | 0.0% | -558.8% | — | — | $4M |
| Sep '24 | — | -$804787 | — | — | — | — | $8M |
| Jun '24 | — | -$3M | — | — | — | — | $13M |
| Mar '24 | — | -$3M | — | — | — | — | $8M |
| Dec '23 | — | -$5M | — | — | — | — | $10M |
| Sep '23 | — | -$5M | — | — | — | — | $8M |
Valuation over time
How the market has priced NEUP against its own fundamentals since 2024-12 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 0.7× (Jun '25) to 0.5× (Jun '26).
Frequently asked questions
Is NEUP growing its revenue and profit?
See the revenue and net-income charts above for Neuphoria Therapeutics Inc.'s multi-year trend.
How much debt does NEUP have?
As of FY2025, Neuphoria Therapeutics Inc. reported — of total debt against $14M of cash.
What is NEUP's profit margin?
In FY2025, gross margin was —, operating margin -7.2%, and net margin -2.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.